Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase III drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Trastuzumab rezetecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trastuzumab rezetecan overview
Trastuzumab rezetecan (SHRA-1811) is under development for the treatment of HER2 expressing or mutated advanced malignant solid tumor, human epidermal growth factor receptor 2 positive breast cancer (HER2+ breast cancer), HER2-negative Advanced Breast Cancer, metastatic breast cancer, metastatic biliary cancer (BTC), advanced non-small cell lung cancer, metastatic colorectal cancer, gastric cancer, cervical cancer, recurrent ovarian cancer and endometrial cancer and adenocarcinoma of the gastroesophageal junction. It is administered by intravenous and parenteral route. The drug candidate is an antibody drug conjugate which acts by targeting cells expressing tyrosine kinase type cell surface receptor HER2.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Trastuzumab rezetecan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
